
Developing
Health·6/2/2026AI summary
Semaglutide Slows Kidney Disease Progression in Type 2 Diabetes Patients
A new analysis shows semaglutide (Ozempic/Wegovy) slows kidney disease progression in type 2 diabetes patients, improving kidney function and survival rates, even with a history of cardiovascular events. The drug mimics GLP-1 hormones and is also popular for weight loss.
A
ABC Top Stories
